Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to primary PCP prophylaxis.
We used 2000–2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a cross-sectional interview project of HIV-infected persons ≥18 years conducted in 18 states. We limited the analysis to persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question “In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take them?” We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported using marijuana (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI] = 1.1–2.4), non-injection drugs other than marijuana (aOR = 1.5, 95% CI = 1.0–2.1), or injection drugs (aOR = 2.3, 95% CI = 1.3–4.1) in the past year; their mental health was “not good” for ≥1 day during the past month (aOR = 1.6, 95% CI = 1.2–2.2); their most recent CD4 count was <200 cells/μL (aOR = 1.6, 95% CI = 1.1–2.2); or taking ART usually (aOR = 9.6, 95% CI = 6.7–13.7) or sometimes/rarely/never (aOR = 18.4, 95% CI = 11.1–30.4), compared with always, as prescribed.
Citation: Heffelfinger JD, Voetsch AC, Nakamura GV, Sullivan PS, McNaghten AD, Huang L (2009) Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia. PLoS ONE 4(3): e5002. https://doi.org/10.1371/journal.pone.0005002
Editor: Ben Marais, University of Stellenbosch, South Africa
Received: November 26, 2008; Accepted: March 1, 2009; Published: March 25, 2009
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: LH was partly funded by the National Institutes of Health (NIH) K24 087713. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection occurring among persons with HIV infection in the United States despite effective prophylactic therapy . During the 1980s, PCP was the AIDS-defining illness for approximately two-thirds of patients, and it was estimated that 75% of HIV-infected persons would develop PCP in their lifetime , . Trimethoprim-sulfamethoxazole (TMP-SMX) was shown to be effective in preventing PCP in persons with AIDS in the late 1980s , and the proportion of cases in which PCP was an AIDS-defining illness decreased appreciably as prescription of TMP-SMX to prevent PCP became the standard of care , . The widespread use of antiretroviral therapy (ART) in the late 1990s led to a further decline in the incidence of PCP . Current Centers for Disease Control and Prevention (CDC) guidelines recommend the initiation of primary PCP prophylaxis for persons with CD4 cell counts less than 200 cells/μL or a history of oropharyngeal candidiasis, and discontinuation of prophylaxis for persons who have responded to ART with an increase in CD4 cell counts to more than 200 cells/μL for greater than 3 months .
Although prophylaxis against PCP is effective, the benefits can only be realized if HIV-positive persons access healthcare, providers appropriately prescribe prophylaxis to persons at risk for PCP, and patients adhere to prescribed PCP prophylaxis. In an analysis of PCP cases diagnosed during 1999–2001, 44% of cases occurred among persons not receiving care, 10% occurred among persons in care who met criteria for prophylaxis but were not prescribed prophylaxis, and 41% occurred among persons prescribed prophylaxis but who were either not adherent to treatment or who developed PCP despite appropriate use . The U.S. Healthy People 2010 goal is for 95% of eligible persons to receive PCP prophylaxis . The proportion of eligible persons prescribed PCP prophylaxis in a large U.S. cohort of HIV-positive persons was 80% , whereas in another study, the proportion of providers who adhered with guidelines for prescribing PCP prophylaxis in federally funded HIV treatment facilities ranged from 80–94% . Lundberg and colleagues found that provider nonadherence to prophylaxis guidelines was uncommon and that patient nonadherence to prophylaxis was the most common reason for the occurrence of PCP . Few studies have examined patient adherence to PCP prophylaxis and reasons for nonadherence. In one study, only 49% of persons reported taking at least 80% of their prescribed PCP prophylaxis in the previous seven days . Presence of family, better mental health, and greater self-efficacy were associated with increased adherence to PCP prophylaxis, whereas injection drug use was associated with nonadherence .
The objective of this analysis was to identify factors associated with and self-reported reasons for nonadherence to primary PCP prophylaxis among HIV-infected persons.
The Supplement to HIV and AIDS Surveillance (SHAS) project was a cross-sectional behavioral surveillance project of persons with HIV infection. The methods have been previously described . In brief, adults (≥18 years) reported with HIV or AIDS through routine case surveillance were eligible for participation. Persons with HIV/AIDS were enrolled using one of two methods: 1) facility-based recruitment of all eligible persons seeking treatment at selected healthcare facilities in 13 cities in 9 states (Denver, Colorado; Hartford and New Haven, Connecticut; Jacksonville, Miami, and Tampa, Florida; Atlanta, Georgia; Chicago, Illinois; Baltimore, Maryland; Detroit, Michigan; Jersey City and Paterson, New Jersey; and Philadelphia, Pennsylvania); and 2) population-based recruitment of all eligible persons in 5 states and in 6 cities and one county in four additional states (Phoenix and Tucson, Arizona; Delaware; Kansas; Los Angeles County, California; Minneapolis/St. Paul, Minnesota; New Mexico; South Carolina; Austin and Houston Texas; and Washington). Most SHAS participants were enrolled in the project soon after they began to receive care for HIV infection. Informed consent was obtained by having the participant read and sign the informed consent form, having the interviewer read the form to the participant and asking the participant to sign the form, or having the interviewer read the form to the participant and indicating on the form that participant provided verbal consent. The project received institutional review board approval at both the CDC and local levels.
From May 2000 through June 2004, SHAS participants were asked about medication history, adherence to medications, and reasons for nonadherence. SHAS has no way to measure adherence with medications independently, but instead relies on self-reported adherence. To determine if respondents were taking PCP prophylaxis and the specific medication(s), they were asked to look at a list of PCP medications on a card. After indicating those medications that were ever prescribed to them, they were asked to indicate which ones they were currently taking. Because there were no questions that specifically addressed whether respondents were taking PCP in this analysis because survey questions did not allow us to determine whether a current prescription for PCP medication was for treatment or secondary prophylaxis against PCP. We limited our analysis to persons who answered the question “Sometimes it is difficult to take medications for many reasons. In the past 30 days, how often were you able to take your PCP medication(s) exactly the way your doctor told you to take them?” Persons answering “always” were considered adherent and those answering “usually”, “sometimes”, or “rarely or never” were considered nonadherent to PCP prophylaxis; persons answering “unknown” to this question and those who did not answer this question were excluded from the analysis because we did not have complete information about their adherence to PCP prophylaxis. Nonadherent persons were asked about the primary reason for nonadherence by asking, “What are some of the reasons why you don't take your PCP medicine(s) as the doctor prescribed?” Respondents were able to provide as many as three reasons for nonadherence. We coded the responses into three categories: 1) side effects; 2) difficulties with access to care or obtaining/taking medications; and 3) problems with scheduling, memory, or lack of perceived necessity. Region of residence was defined by the U.S. Census Bureau. Risk for recent alcohol abuse was defined as answering “yes” to two or more CAGE questions  and reporting alcohol use in the previous year. The daily pill burden was calculated by adding the number of medications prescribed for ART, prophylaxis against opportunistic infections, and other conditions. Assessment of mental health during the previous month was determined by the answer to the question, “Now thinking about your mental health, which includes stress, depression, and problems with emotions, for how many days during the past 30 days was your mental health not good?” Respondents were asked to look at a list of “HIV/AIDS medicines” (ART medications) and tell the interviewer which of the listed medications they had ever taken and which they were currently taking. Adherence to ART was defined for persons who reported having a current prescription for ART and who answered the question “In the past 30 days, how often were you able to take your HIV/AIDS medicines exactly the way your doctor told you to take them?” Persons could answer “always”, “usually”, “sometimes”, “rarely or never”, or “unknown”, and their adherence to ART medicines was categorized accordingly, although those answering “sometimes” or “rarely or never” were grouped together for this analysis. Illicit drug use was categorized as no drug use, use of marijuana only, use of non-injection drugs other than marijuana, and use of injection drugs in the past year. In addition, for some analyses, injection drug use was categorized as injection drug use versus no injection drug use in the past year.
Statistical testing for differences (p<0.05) between factors associated with adherence and nonadherence to PCP prophylaxis was performed using chi-squared or Fisher's exact test, as appropriate. We used multivariable logistic regression models using STATA version 8.0 (STATA Corporation, Corpus Christi, TX) to calculate adjusted odds ratios and 95% confidence intervals for factors associated with nonadherence to PCP prophylaxis. Because region of residence and year of SHAS interview were identified as likely confounding factors of nonadherence to PCP prophylaxis a priori, these variables were included in all multivariable models. In multivariable analyses, controlling for region of residence and year of SHAS interview, preliminary models included factors that were associated (p≤0.10) with nonadherence to primary PCP prophylaxis in bivariate analyses. We performed stepwise elimination to remove factors that were not significantly associated (p>0.05) with nonadherence . We assessed all possible two-way interactions between variables using a forward selection model using SAS version 9.1 (SAS Institute, Cary, NC), with a p-value for entry that was corrected for multiple comparisons between the number of possible interaction terms. We conducted a sensitivity analysis using a more restrictive definition of nonadherence (having only sometimes, rarely, or never taken PCP medications exactly as prescribed during the past month). Because the most important indication for PCP prophylaxis is a low CD4 cell count, we also conducted multivariable analysis after restricting the data set to persons with CD4 counts less than 200 cells/μL.
Of the 11,503 persons asked to participate in SHAS, 1,666 (18.3% of interviewed) respondents who had a prescription for primary PCP prophylaxis and complete information about adherence to PCP prophylaxis were included in the analysis. Eligibility and selection criteria for subjects included in this analysis of nonadherence to PCP prophylaxis are summarized in Figure 1. Among these 1,666 persons, 76.8% were male, 75.4% considered themselves to be non-Hispanic black or Hispanic, and the median age was 40 (range: 19–75) years. Seventy-nine percent of subjects who reported having a current prescription for PCP medications were prescribed TMP-SMX.
Three hundred five (18.3%) respondents were nonadherent with primary PCP prophylaxis during the month preceding their interview. On bivariate analysis, nonadherence to primary PCP prophylaxis was associated with year of SHAS interview, illicit drug use in the past year, current risk for alcohol abuse, description of mental health as “not good” for ≥1 day in the past month, most recent CD4 count <200 cells/μL, most recent HIV viral load >5,000 copies/mL, and nonadherence to ART in the past month (Table 1). Sex, age group, race/ethnicity, income, having health insurance, education, U.S. region of residence, living situation, current PCP medication(s) prescribed, daily pill burden, and type of recruitment were not associated with nonadherence to PCP prophylaxis.
Multivariable analysis was performed to identify factors that were independently associated with nonadherence to primary PCP prophylaxis. Controlling for region of residence and year of interview, factors that were independently associated with nonadherence to primary PCP prophylaxis were use of marijuana, non-injection drugs other than marijuana, and injection drugs in the past year; description of mental health as not good for ≥1 day in the past month; most recent CD4 count <200 cells/μL; and having taken ART usually or sometimes/rarely/never as prescribed, having taken ART but having unknown or missing information about adherence to ART, or not having taken ART in the past month (Table 2). No significant interaction was found. The risk of nonadherence to PCP prophylaxis increased with the level of nonadherence to ART, being approximately twice as high among persons who reported having sometimes/rarely/never been adherent with ART as it was among those who reported having usually been adherent with ART during the preceding month.
Limiting the multivariable analysis to persons whose most recent CD4 count was <200 cells/μL and controlling for region of residence and year of interview, injection drug use in the past year (adjusted odds ratio [aOR]: 2.3; 95% confidence interval [CI]: 1.1–4.9) and having taken ART usually (aOR: 9.2; 95% CI: 5.5–15.5) or sometimes/rarely/never (aOR: 26.8; 95% CI: 13.1–54.5) as prescribed, having taken ART but having unknown or missing information about adherence to ART (aOR: 2.6; 95% CI: 1.2–5.3), or not having taken ART (aOR: 4.8; 95% CI: 2.6–9.1) in the past month were independently associated with nonadherence to primary PCP prophylaxis. The risk of nonadherence to PCP prophylaxis was almost three times as high among persons who reported having sometimes/rarely/never been adherent with ART as it was among those who reported having usually been adherent with ART during the preceding month.
When we used the more restrictive definition of nonadherence to PCP prophylaxis during the past month (i.e., defining it as taking PCP medications sometimes, rarely, or never), our findings on multivariable analysis did not change appreciably (data not shown). However, description of mental health as not good for ≥1 day in the past month did not remain in the model and injection drug use during the past year was no longer an independent risk factor for nonadherence using the more restrictive definition of nonadherence.
Of the 305 persons who reported that they did not take primary PCP prophylaxis exactly as prescribed during the month before interview, 264 (86.6%) reported the primary reason why they did not do so. Side effects were cited by 21.6%; difficulties with access to care or obtaining/taking medications were reported by 13.6%; and problems with scheduling, difficulty remembering to take the medication(s), or lack of perceived necessity were listed by 64.8% of subjects (Table 3). The most common reason cited for not taking PCP prophylaxis was forgetting to take it.
In a large cohort of persons living with HIV infection, we found that almost one-fifth were nonadherent to primary PCP prophylaxis. We found that nonadherence to PCP prophylaxis was associated with illicit drug use, mental health issues including depression, nonadherence to prescribed ART, and low CD4 cell count.
Our findings regarding illicit drug use are consistent with those of several studies evaluating adherence to ART , , , , , , , , however current drug use was not found to be an independent risk factor in either study evaluating risk factors for nonadherence to PCP prophylaxis , . We did not find nonadherence to be associated with age, race/ethnicity, or daily pill burden, factors which have previously been reported to be associated with increased risk for nonadherence to PCP prophylaxis and/or ART.
Consistent with our findings, Eldred and colleagues found that a high Mental Health Inventory-5 score, which indicates better mental health, was associated with adherence to PCP prophylaxis . Lundberg and colleagues found that persons with current psychiatric illness were more likely to be nonadherent to PCP prophylaxis; however they did not find this condition to be an independent risk factor for nonadherence . Additionally, mental health issues have been associated with nonadherence to ART in several studies , , , , . It is possible, though, that persons with better mental health may report adherence to medications more accurately than persons with poorer mental health.
Persons who reported being nonadherent to primary PCP prophylaxis were much more likely to report also being nonadherent to ART, which is consistent with the findings of Lundberg and associates . We found that the risk of nonadherence to PCP prophylaxis was highest among those with the highest levels of reported nonadherence to ART medications.
We found that low CD4 cell count was independently associated with nonadherence to PCP prophylaxis. However, 29% of respondents reported having recent CD4 cell counts that were ≥200 cells/μL, and 32% could not provide information about their most recent CD4 cell count. Respondents whose most recent CD4 cell counts were ≥200 cells/μL may have been started on PCP prophylaxis based on a declining trend in CD4 cell counts, may not have had CD4 cell counts that were ≥200 cells/μL for at least 3 months, or may not have accurately recalled their most recent CD4 count. When we limited our analysis to persons who reported that their most recent CD4 cell count was <200 cells/μL, our findings did not change appreciably. Among subjects reporting they had a CD4 count <200 cells/μL, recent injection drug use and nonadherence to ART remained independent predictors for nonadherence to PCP prophylaxis; however, non-injection drug use did not remain an independent risk factor.
Although several studies have found that nonadherence to PCP prophylaxis and/or ART was associated with age , , ,  or race/ethnicity , , we did not find nonadherence to PCP prophylaxis to be independently associated with these or other sociodemographic characteristics. In addition, we found that daily pill burden was not associated with nonadherence to PCP prophylaxis, which contradicts the findings of several studies that have found that an increased number of ART pills taken daily is associated with nonadherence to PCP prophylaxis or ART , , . Our findings may differ from those of other investigators because we were able to control more completely for potentially confounding variables or, with respect to the number of pills taken daily, because we used a different measure for pill burden that included all medications prescribed and not just ART medications.
Forgetting to take PCP prophylaxis was the most common reason provided by participants in our analysis, followed by concern about side effects and inability to fit taking the medication(s) into one's schedule, which parallels reasons given for nonadherence to ART among SHAS participants in a separate analysis . Forgetting to take medications has previously been reported to be an important reason for nonadherence to PCP prophylaxis , ART , and prescribed therapy for other conditions , . Structural barriers such as limited access to healthcare or medications were not prominent as reasons for nonadherence in our analysis.
This study has several imitations. Because this was an interview study, our findings are subject to recall and social desirability bias . However, asking subjects about their adherence to primary PCP prophylaxis in the month before the interview should have reduced recall bias. Because social desirability would be expected to lead subjects to underreport nonadherence to medications, our estimate may be a minimum one . Because hospitals that participated in areas which used facility-based recruitment may not have been representative of all facilities that provide care to HIV-infected persons in these areas, and persons recruited and interviewed by SHAS sites were not representative of all HIV-infected persons, or of all HIV-infected persons in care, our findings are subject to selection bias. In addition, limited or no information was collected in the interview about a number of factors that may be important for nonadherence, including social support, isolation, treatment efficacy, and self-efficacy , . Despite these limitations, the SHAS surveillance system represents the largest survey of HIV-infected persons in the U.S. and therefore has the most complete data to assess self-reported adherence to PCP prophylaxis.
Nonadherence to PCP prophylaxis is an important contributor to adverse clinical events, and nonadherence to relatively simple regimens used to protect against PCP suggests that there may be greater challenges with adherence to ART regimens, which are more complicated . We found that an appreciable proportion of HIV-infected persons were nonadherent to prescribed medications to prevent PCP, and that persons who were nonadherent to PCP prophylaxis were much more likely to be nonadherent to ART. Providers should inquire about adherence to prescribed medications to prevent PCP at every HIV care visit, paying particular attention to persons who use illicit drugs, have mental health issues, have low CD4 cell counts, and are nonadherent to ART or medications prescribed for other conditions. These variables should be triggers for providers to consider the complex issue of adherence. Providers should take every opportunity to educate their patients about the importance of compliance with ART and medications to prevent opportunistic infections, discuss the possible side effects of prescribed medications, and assist patients about ways to remember to take their medications as prescribed. In addition, providers should regularly ask HIV-infected patients about illicit drug use and mental health issues and treat or refer persons with substance abuse and/or mental illnesses to ensure optimal adherence to prescribed medications. Although few studies have evaluated factors associated with nonadherence or ways to improve adherence to medications to prevent PCP, the commonality of associated factors for nonadherence to PCP prophylaxis and ART suggests that interventions for ART adherence may be also be used to improve adherence to PCP prophylaxis. Studies evaluating adherence to ART, prophylaxis against PCP and other opportunistic infections, and prescribed medications for other conditions may shed light on how to improve adherence and quality of life and reduce morbidity and mortality among HIV-infected persons.
We would like to acknowledge the contributions of the SHAS project principal investigators and project officers: Vjollca Berisha and Rick DeStephens, Arizona Department of Public Health; Arthur Davidson, Denver Health and Hospital Authority; Aaron Roome, Connecticut Department of Public Health; James Welch, Delaware Department of Public Health; Rebecca Grigg and Pam Lowell, Florida Department of Health; Jeffrey Lenox and Alan Fann, Emory University School of Medicine; Marcia Wolverton, Houston Department of Health and Human Services; Fran Eury, Illinois Department of Public Health; Jeni Mulqueen, Anthony Merriweather, and Gail Hansen, Kansas Department of Health and Environment; Amy Rock Wohl and Denise Johnston, Los Angeles County Department of Health; Ellen Caldeira, Maryland Department of Health and Mental Hygiene; Eve Mokotoff, Sha Juan Colbert, and Shanell McGoy, Michigan Department of Community Health; Richard Danila and Don Stiepan, Minnesota Department of Public Health; Sally D'Errico, New Jersey Department of Health; Mack Sewell, New Mexico Department of Public Health; Kathleen Brady, Philadelphia Department of Public Health; Terri Stephens, South Carolina Department of Health and Environmental Control; Sharon Melville and Sylvia Odem, Texas Department of Health; and Maria Courogen, Washington State Department of Health.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Analyzed the data: JH ACV GVN PSS. Contributed reagents/materials/analysis tools: JH ACV GVN PSS ADM LH. Wrote the paper: JH.
- 1. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30: Suppl 1S5–14.JE KaplanD. HansonMS DworkinT. FrederickJ. Bertolli2000Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.Clin Infect Dis30Suppl 1S514
- 2. Hay JW, Osmond DH, Jacobson MA (1988) Projecting the medical costs of AIDS and ARC in the United States. J Acquir Immune Defic Syndr 1: 466–485.JW HayDH OsmondMA Jacobson1988Projecting the medical costs of AIDS and ARC in the United States.J Acquir Immune Defic Syndr1466485
- 3. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, et al. (2004) Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 10: 1713–1720.A. MorrisJD LundgrenH. MasurPD WalzerDL Hanson2004Current epidemiology of Pneumocystis pneumonia.Emerg Infect Dis1017131720
- 4. Fischl MA, Dickinson GM, La Voie L (1988) Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 259: 1185–1189.MA FischlGM DickinsonL. La Voie1988Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.JAMA25911851189
- 5. CDC (1990) HIV/AIDS Surveillance Report, 1989CDC1990HIV/AIDS Surveillance Report, 1989
- 6. CDC (1993) HIV/AIDS Surveillance Report, 1992CDC1993HIV/AIDS Surveillance Report, 1992
- 7. Kaplan JE, Masur H, Holmes KK (2002) Guidelines for preventing opportunistic infections among HIV-infected persons–2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51: 1–52.JE KaplanH. MasurKK Holmes2002Guidelines for preventing opportunistic infections among HIV-infected persons–2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.MMWR Recomm Rep51152
- 8. US Department of Health and Human Services (2000) Healthy People 2010: understanding and improving health. 2nd ed. 2000US Department of Health and Human Services2000Healthy People 2010: understanding and improving health. 2nd ed. 2000
- 9. Teshale EH, Hanson DL, Wolfe MI, Brooks JT, Kaplan JE, et al. (2007) Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994–2003. Clin Infect Dis 44: 879–883.EH TeshaleDL HansonMI WolfeJT BrooksJE Kaplan2007Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994–2003.Clin Infect Dis44879883
- 10. Kaplan JE, Parham DL, Soto-Torres L, van Dyck K, Greaves JA, et al. (1999) Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States. J Acquir Immune Defic Syndr 21: 228–235.JE KaplanDL ParhamL. Soto-TorresK. van DyckJA Greaves1999Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States.J Acquir Immune Defic Syndr21228235
- 11. Lundberg BE, Davidson AJ, Burman WJ (2000) Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS 14: 2559–2566.BE LundbergAJ DavidsonWJ Burman2000Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure.AIDS1425592566
- 12. Eldred LJ, Wu AW, Chaisson RE, Moore RD (1998) Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 18: 117–125.LJ EldredAW WuRE ChaissonRD Moore1998Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease.J Acquir Immune Defic Syndr Hum Retrovirol18117125
- 13. Buehler JW, Diaz T, Hersh BS, Chu SY (1996) The supplement to HIV-AIDS Surveillance project: an approach for monitoring HIV risk behaviors. Public Health Rep 111: Suppl 1133–137.JW BuehlerT. DiazBS HershSY Chu1996The supplement to HIV-AIDS Surveillance project: an approach for monitoring HIV risk behaviors.Public Health Rep111Suppl 1133137
- 14. Maisto SA, Saitz R (2003) Alcohol use disorders: screening and diagnosis. Am J Addict 12: Suppl 1S12–25.SA MaistoR. Saitz2003Alcohol use disorders: screening and diagnosis.Am J Addict12Suppl 1S1225
- 15. Agresti A (2002) Categorical Data Analysis. (Second edition). Hoboken, New Jersey: ohn Wiley and Sons, Inc. A. Agresti2002Categorical Data Analysis. (Second edition).Hoboken, New Jerseyohn Wiley and Sons, Inc
- 16. Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, et al. (2004) Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 45: 394–402.A. AmmassariA. AntinoriMS AloisiMP TrottaR. Murri2004Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons.Psychosomatics45394402
- 17. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, et al. (2002) Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 17: 377–381.JH ArnstenPA DemasRW GrantMN GourevitchH. Farzadegan2002Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.J Gen Intern Med17377381
- 18. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, et al. (2004) Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 19: 1111–1117.KM BergPA DemasAA HowardEE SchoenbaumMN Gourevitch2004Gender differences in factors associated with adherence to antiretroviral therapy.J Gen Intern Med1911111117
- 19. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, et al. (2002) A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 16: 2175–2182.AA HowardJH ArnstenY. LoD. VlahovJD Rich2002A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.AIDS1621752182
- 20. Lafeuillade A (2001) Factors affecting adherence and convenience in antiretroviral therapy. Int J STD AIDS 12: Suppl 418–24.A. Lafeuillade2001Factors affecting adherence and convenience in antiretroviral therapy.Int J STD AIDS12Suppl 41824
- 21. Martini M, Recchia E, Nasta P, Castanotto D, Chiaffarino F, et al. (2004) Illicit drug use: can it predict adherence to antiretroviral therapy? Eur J Epidemiol 19: 585–587.M. MartiniE. RecchiaP. NastaD. CastanottoF. Chiaffarino2004Illicit drug use: can it predict adherence to antiretroviral therapy?Eur J Epidemiol19585587
- 22. Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D, et al. (2004) Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis 39: 1190–1198.AR MossJA HahnS. PerryED CharleboisD. Guzman2004Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study.Clin Infect Dis3911901198
- 23. Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, et al. (2007) Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS ONE 2: e552.PS SullivanML CampsmithGV NakamuraEB BegleyJ. Schulden2007Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy.PLoS ONE2e552
- 24. Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, et al. (2006) Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 41: 477–485.MP CarrieriC. LeportC. ProtopopescuJP CassutoE. Bouvet2006Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase.J Acquir Immune Defic Syndr41477485
- 25. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J (1999) Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 13: 1763–1769.V. GordilloJ. del AmoV. SorianoJ. Gonzalez-Lahoz1999Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.AIDS1317631769
- 26. Starace F, Ammassari A, Trotta MP, Murri R, De Longis P, et al. (2002) Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31: Suppl 3S136–139.F. StaraceA. AmmassariMP TrottaR. MurriP. De Longis2002Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy.J Acquir Immune Defic Syndr31Suppl 3S136139
- 27. Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, et al. (1992) Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 92: 495–502.JH SametH. LibmanKA StegerRK DhawanJ. Chen1992Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic.Am J Med92495502
- 28. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, et al. (1980) Can simple clinical measurements detect patient noncompliance? Hypertension 2: 757–764.RB HaynesDW TaylorDL SackettES GibsonCD Bernholz1980Can simple clinical measurements detect patient noncompliance?Hypertension2757764
- 29. Sumartojo E (1993) When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 147: 1311–1320.E. Sumartojo1993When tuberculosis treatment fails. A social behavioral account of patient adherence.Am Rev Respir Dis14713111320
- 30. Sackett DL (1979) Bias in analytic research. J Chronic Dis 32: 51–63.DL Sackett1979Bias in analytic research.J Chronic Dis325163
- 31. Murri R, Ammassari A, Trotta MP, De Luca A, Melzi S, et al. (2004) Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 19: 1104–1110.R. MurriA. AmmassariMP TrottaA. De LucaS. Melzi2004Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance.J Gen Intern Med1911041110
- 32. Altice FL, Mostashari F, Friedland GH (2001) Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 28: 47–58.FL AlticeF. MostashariGH Friedland2001Trust and the acceptance of and adherence to antiretroviral therapy.J Acquir Immune Defic Syndr284758
- 33. Holmes WC, Pace JL (2002) HIV-seropositive individuals' optimistic beliefs about prognosis and relation to medication and safe sex adherence. J Gen Intern Med 17: 677–683.WC HolmesJL Pace2002HIV-seropositive individuals' optimistic beliefs about prognosis and relation to medication and safe sex adherence.J Gen Intern Med17677683